AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Supernus Pharmaceuticals Appoints Frank Mottola as Chief Technical Operations Officer.
ByAinvest
Monday, Aug 4, 2025 8:12 am ET1min read
Supernus Pharmaceuticals has appointed Frank Mottola as Chief Technical Operations Officer, effective June 16, 2025. Mottola, previously the company's Senior Vice President of Quality, GMP Operations and IT, was recommended by the Compensation Committee and approved by the Board of Directors.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) has announced the appointment of Frank Mottola as its Chief Technical Operations Officer, effective June 16, 2025. Mottola, previously serving as Senior Vice President of Quality, GMP Operations and IT, has been recommended by the Compensation Committee and approved by the Board of Directors.Mottola brings extensive experience in quality and operations to the role. His appointment comes at a critical juncture for Supernus, as the company continues to expand its portfolio and diversify its revenue streams through strategic acquisitions and product development. Mottola’s leadership will be instrumental in driving operational excellence and technological innovation, which are key to achieving the company’s growth objectives.
The appointment of Mottola follows Supernus’s recent acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE), which added the innovative commercial product ZURZUVAE® (zuranolone) and a novel CNS discovery platform to the company’s portfolio. This acquisition is expected to accelerate mid- to long-term revenue and cash flow growth and further diversify the revenue base [1].
Mottola’s role will be crucial in integrating the new assets and ensuring smooth operations as Supernus continues to expand its footprint in the neuropsychiatric conditions market. His background in quality and GMP operations will be particularly valuable in maintaining the high standards required for the development and commercialization of CNS therapies.
Supernus has been making significant strides in its strategic development, with a focus on diversifying its revenue streams and enhancing its product pipeline. The appointment of Mottola aligns with these strategic goals and underscores the company’s commitment to operational excellence and innovation.
References:
[1] https://www.biospace.com/press-releases/supernus-pharmaceuticals-completes-acquisition-of-sage-therapeutics
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet